International Journal of Clinical Research

Objective To analyze the role of continuous blood purification therapy in severe sepsis. Methods Randomly divide patients with severe sepsis admitted to our hospital from December 2023 to December 2024 (n=80). The experimental group received continuous blood purification therapy, while the control group received routine treatment. Compare indicators such as adverse reactions. Results Regarding urea nitrogen and creatinine: After treatment, the experimental group decreased to (12.83 ± 3.04) mmol/L and (149.71 ± 24.31) umol/L, while the control group increased to (18.53 ± 3.25) mmol/L and (176.23 ± 27.19) umol/L, with significant differences (P<0.05). The total effective rate was 97.5% in the experimental group and 77.5% in the control group, P＜0.05. CRP and IL-10: After treatment: the experimental group had (50.04 ± 7.28) mg/L and (38.92 ± 6.03) ug/L, while the control group had (57.93 ± 8.14) mg/L and (35.17 ± 3.34) ug/L, with significant differences (P<0.05). Adverse reactions: 2.5% in the experimental group and 17.5% in the control group, P＜0.05. Conclusion Continuous blood purification therapy has significant effects on severe sepsis patients, with better improvement in renal function and inflammatory factors, and fewer adverse reactions.

Severe sepsis; Adverse reactions; Continuous blood purification; Inflammatory factors